Conference Proceedings

Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.

Michael J Overman, Sara Lonardi, Francesco Leone, Raymond S McDermott, Michael A Morse, Ka Yeung Mark Wong, Bart Neyns, Joseph L Leach, Pilar Garcia Alfonso, James J Lee, Andrew Hill, Heinz-Josef Lenz, Jayesh Desai, Rebecca A Moss, Z Alexander Cao, Jean-Marie Ledeine, Hao Tang, Scott Kopetz, Thierry Andre

JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2017

Abstract

519 Background: Approximately 4% of metastatic colorectal cancers (mCRCs) are associated with high microsatellite instability (MSI-H), indicating a deficient DNA mismatch repair (dMMR) system. dMMR/MSI-H CRC exhibits an increased tumor neoantigen load and immune cell infiltration and is hypothesized to be targetable by immune checkpoint inhibitors. CheckMate 142 (NCT02060188) evaluates the efficacy and safety of nivolumab (nivo) in patients (pts) with dMMR/MSI-H mCRC. Methods: Pts with dMMR/MSI-H mCRC who progressed on/were intolerant to ≥1 prior line of therapy received nivo 3 mg/kg (nivo 3) every 2 weeks (Q2W). The primary endpoint was objective response rate (ORR) per investigator (INV)...

View full abstract